1226. Readily-Available Antibiotic Formulations to Improve Outcomes in Cancer Outpatients with Severe Sepsis and Septic Shock: the “Sepsis STAT Pack”. 
Session: Poster Abstract Session: Transplant Screenings and Evaluation and Empiric and Pre-Emptive Therapy
Friday, October 9, 2015
Room: Poster Hall
Posters
  • SSP IDWeek_poster_final_30sep15.pdf (783.0 kB)
  • Background: Cancer patients are at high risk for severe sepsis (SS) and septic shock (SSh) and delay to effective antimicrobial therapy (ABx) is strongly associated with increased mortality. Anti-pseudomonal beta-lactam intravenous monotherapy is equally effective and less toxic than combination therapy for uncomplicated neutropenic fever, but combination therapy may be superior for more severe disease.  

    Methods: We implemented a clinical algorithm to simplify timely and effective empiric ABx and other resuscitative care to cancer outpatients with SS/SSh prior to hospital admission. Triple therapy with meropenem, tobramycin and linezolid or alternatives such as aztreonam for penicillin-allergic patients can be co-administered and provides broad coverage for resistant organisms typically encountered in this population. A pre-printed order form triggered dispensing of kits containing ABx, fluids and dexamethasone. We performed a retrospective cohort study to assess the impact of this strategy. 

    Results: From 1/1/08 through 1/31/12, 162 patients met inclusion criteria. Median age was 53 (IQR: 42 – 63) years and 65% were male. The majority of patients (87%) had hematopoetic malignancies. 77 (48%) were hematopoietic stem cell transplant recipients and 80 (49%) were neutropenic. SSh was diagnosed in 25 patients (15%), SS in 46 (28%), sepsis in 72 (44%) alternative diagnosis in 6 (4%) and infection without systemic inflammatory response syndrome in 13 (8%). Median time from clinical encounter to ABx administration was 114 (IQR: 60 – 179) minutes, 93% had blood cultures drawn prior to ABx, 46% received dexamethasone and 99% had crystalloid infusion started before hospital transfer. De-escalation on hospital day 1 occurred in 95% of persons admitted. 44% of 25 persons with SSh received vasopressors. 71 persons (44%) had bacteremia and 18% of 93 isolates were multidrug resistant. Possible nephrotoxicity occurred in 4 patients. 30 day mortality was 6/160 (4%) including 3/71 (4%) with SS/SSh. 

    Conclusion: A program to simplify choice of aggressive empiric ABx among cancer patients presenting to an ambulatory clinic with suspected sepsis was associated with unprecedented survival in those with SS/SSh, without excessive adverse events or inappropriately long empiric ABx durations.

    Jason Goldman, MD1,2,3,4, Amelia Gallaher, BS5, Rupali Jain, PharmD6, Zachary Stednick, MPH3, Manoj Menon, MD2,3,7, Stephen Schwartz, PhD4,8, Paul Pottinger, MD, FIDSA1,2 and Corey Casper, MD, MPH, FIDSA1,2,3,4, (1)Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, (2)Seattle Cancer Care Alliance, Seattle, WA, (3)Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, (4)Department of Epidemiology, University of Washington, Seattle, WA, (5)School of Medicine, University of Washington, Seattle, WA, (6)School of Pharmacy, University of Washington, Seattle, WA, (7)Division of Medical Oncology, University of Washington, Seattle, WA, (8)Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA

    Disclosures:

    J. Goldman, None

    A. Gallaher, None

    R. Jain, None

    Z. Stednick, None

    M. Menon, None

    S. Schwartz, None

    P. Pottinger, None

    C. Casper, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.